clinical trial · NCT06273254
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Bioequivalence StudySacubitril and Valsartan Tablets 49mg/51mgEntresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
brief summary
Primary objective is to is to evaluate the bioequivalence of two formulations
started
Apr 1, 2024
primary completion
May 1, 2024
completion
Sep 1, 2024
last updated
Feb 22, 2024
detailed description
To evaluate the bioequivalence of two formulations of sacubitril/valsartan 49 mg/51 mg film coated tablets, Entresto® (Reference) and Sacubitril and Valsartan Tablets 49mg/51mg (Test), after a single oral dose administration in healthy Thai subjects under fasting conditions
official title
A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 49 mg/51 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol